

TBC1D7 siRNA (h): sc-95616

BACKGROUND

TBC1D7 (TBC1 domain family, member 7), also known as PIG51 or cell migration-inducing protein 23, is a 293 amino acid protein that localizes to the cytoplasmic vesicle of the endomembrane in conjunction with the hamartin-tuberin complex. TBC1D7 is thought to function in GTPase activation of Rab proteins, and may negatively regulate hamartin through FRAP activation. Existing as two alternatively spliced isoforms, TBC1D7 is highly expressed in heart and is found at low levels in placenta, kidney and liver. TBC1D7 contains one Rab-GAP TBC domain and is encoded by a gene that maps to human chromosome 6. Chromosome 6 contains 170 million base pairs and comprises nearly 6% of the human genome. Deletion of a portion of the q arm of chromosome 6 is associated with early onset intestinal cancer, suggesting the presence of a cancer susceptibility locus. Additionally, Porphyria cutanea tarda, Parkinson's disease, Stickler syndrome and a susceptibility to bipolar disorder are all associated with genes that map to chromosome 6.

REFERENCES

1. Brunner, H.G., et al. 1994. A Stickler syndrome gene is linked to chromosome 6 near the COL11A2 gene. *Hum. Mol. Genet.* 3: 1561-1564.
2. Cesari, R., et al. 2003. Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25-q27. *Proc. Natl. Acad. Sci. USA* 100: 5956-5961.
3. Nakashima, A., et al. 2007. Identification of TBC7 having TBC domain as a novel binding protein to TSC1-TSC2 complex. *Biochem. Biophys. Res. Commun.* 361: 218-223.
4. Bläker, H., et al. 2008. Recurrent deletions at 6q in early age of onset non-HNPCC- and non-FAP-associated intestinal carcinomas. Evidence for a novel cancer susceptibility locus at 6q14-q22. *Genes Chromosomes Cancer* 47: 159-164.
5. Ishibashi, K., et al. 2009. Identification and characterization of a novel Tre-2/Bub2/Cdc16 (TBC) protein that possesses Rab3A-GAP activity. *Genes Cells* 14: 41-52.
6. Fan, J., et al. 2010. Linkage disequilibrium mapping of the chromosome 6q21-22.31 bipolar I disorder susceptibility locus. *Am. J. Med. Genet. B Neuropsychiatr. Genet.* 153B: 29-37.

CHROMOSOMAL LOCATION

Genetic locus: TBC1D7 (human) mapping to 6p24.1.

PRODUCT

TBC1D7 siRNA (h) is a pool of 3 target-specific 19-25 nt siRNAs designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10 μ M solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see TBC1D7 shRNA Plasmid (h): sc-95616-SH and TBC1D7 shRNA (h) Lentiviral Particles: sc-95616-V as alternate gene silencing products.

For independent verification of TBC1D7 (h) gene silencing results, we also provide the individual siRNA duplex components. Each is available as 3.3 nmol of lyophilized siRNA. These include: sc-95616A, sc-95616B and sc-95616C.

STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20° C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20° C, avoid contact with RNases and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330 μ l of the RNase-free water provided. Resuspension of the siRNA duplex in 330 μ l of RNase-free water makes a 10 μ M solution in a 10 μ M Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

APPLICATIONS

TBC1D7 siRNA (h) is recommended for the inhibition of TBC1D7 expression in human cells.

SUPPORT REAGENTS

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10 μ M in 66 μ l. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44233, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.

GENE EXPRESSION MONITORING

TBC1D7 (C-9): sc-514595 is recommended as a control antibody for monitoring of TBC1D7 gene expression knockdown by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000) or immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500).

To ensure optimal results, the following support reagents are recommended: 1) Western Blotting: use m-IgG κ BP-HRP: sc-516102 or m-IgG κ BP-HRP (Cruz Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz Marker[™] Molecular Weight Standards: sc-2035, UltraCruz[®] Blocking Reagent: sc-516214 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use m-IgG κ BP-FITC: sc-516140 or m-IgG κ BP-PE: sc-516141 (dilution range: 1:50-1:200) with UltraCruz[®] Mounting Medium: sc-24941 or UltraCruz[®] Hard-set Mounting Medium: sc-359850.

RT-PCR REAGENTS

Semi-quantitative RT-PCR may be performed to monitor TBC1D7 gene expression knockdown using RT-PCR Primer: TBC1D7 (h)-PR: sc-95616-PR (20 μ l). Annealing temperature for the primers should be 55-60° C and the extension temperature should be 68-72° C.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.